Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milan Radovich

Showing results (31-40 of 102) with videos related to

Pageof 11
Sort By:
Nature Communications|February 28, 2018
Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genesIbrahim Numanagić, Salem Malikić, Michael Ford, et al.
JCO Precision Oncology|September 14, 2020
Severe Capecitabine Toxicity Associated With a Rare <i>DPYD</i> Variant Identified Through Whole-Genome SequencingReynold C Ly, Remington E Schmidt, Patrick J Kiel, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 22, 2013
A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degenerationJohn W Kitchens, Nawal Kassem, William Wood, et al.
Bioinformatics (Oxford, England)|December 22, 2017
Computational identification of micro-structural variations and their proteogenomic consequences in cancerYen-Yi Lin, Alexander Gawronski, Faraz Hach, et al.
Breast Cancer Research and Treatment|September 12, 2008
Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashesBryan P Schneider, Milan Radovich, David A Flockhart, et al.
JCO Precision Oncology|January 16, 2018
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103Bryan P Schneider, Fei Shen, Guanglong Jiang, et al.
Oncotarget|October 13, 2016
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African AmericansBryan P Schneider, Dongbing Lai, Fei Shen, et al.
Science Translational Medicine|February 11, 2021
Targeted immunotherapy for HER2-low breast cancer with 17p lossYujing Li, Yifan Sun, Michael Kulke, et al.
Frontiers in Cardiovascular Medicine|January 2, 2023
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancerElizabeth J Rowe, Tyler Shugg, Reynold C Ly, et al.
Nature Communications|March 19, 2025
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvalsGeorge W Sledge, Takayuki Yoshino, Joanne Xiu, et al.
Pageof 11

Showing results (31-40 of 102) with videos related to

Sort By:
Pageof 11
Nature Communications|February 28, 2018
Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genesIbrahim Numanagić, Salem Malikić, Michael Ford, et al.
JCO Precision Oncology|September 14, 2020
Severe Capecitabine Toxicity Associated With a Rare <i>DPYD</i> Variant Identified Through Whole-Genome SequencingReynold C Ly, Remington E Schmidt, Patrick J Kiel, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 22, 2013
A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degenerationJohn W Kitchens, Nawal Kassem, William Wood, et al.
Bioinformatics (Oxford, England)|December 22, 2017
Computational identification of micro-structural variations and their proteogenomic consequences in cancerYen-Yi Lin, Alexander Gawronski, Faraz Hach, et al.
Breast Cancer Research and Treatment|September 12, 2008
Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashesBryan P Schneider, Milan Radovich, David A Flockhart, et al.
JCO Precision Oncology|January 16, 2018
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103Bryan P Schneider, Fei Shen, Guanglong Jiang, et al.
Oncotarget|October 13, 2016
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African AmericansBryan P Schneider, Dongbing Lai, Fei Shen, et al.
Science Translational Medicine|February 11, 2021
Targeted immunotherapy for HER2-low breast cancer with 17p lossYujing Li, Yifan Sun, Michael Kulke, et al.
Frontiers in Cardiovascular Medicine|January 2, 2023
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancerElizabeth J Rowe, Tyler Shugg, Reynold C Ly, et al.
Nature Communications|March 19, 2025
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvalsGeorge W Sledge, Takayuki Yoshino, Joanne Xiu, et al.
Pageof 11